359 related articles for article (PubMed ID: 18549664)
1. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.
Réa-Neto A; Niederman M; Lobo SM; Schroeder E; Lee M; Kaniga K; Ketter N; Prokocimer P; Friedland I
Curr Med Res Opin; 2008 Jul; 24(7):2113-26. PubMed ID: 18549664
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.
Chastre J; Wunderink R; Prokocimer P; Lee M; Kaniga K; Friedland I
Crit Care Med; 2008 Apr; 36(4):1089-96. PubMed ID: 18379232
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
Alvarez-Lerma F; Insausti-Ordeñana J; Jordá-Marcos R; Maraví-Poma E; Torres-Martí A; Nava J; Martínez-Pellús A; Palomar M; Barcenilla F;
Intensive Care Med; 2001 Mar; 27(3):493-502. PubMed ID: 11355117
[TBL] [Abstract][Full Text] [Related]
4. Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators.
Kollef MH; Nathwani D; Merchant S; Gast C; Quintana A; Ketter N
Crit Care; 2010; 14(3):R84. PubMed ID: 20459721
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
[TBL] [Abstract][Full Text] [Related]
6. [Treatment study of hospital acquired pneumonia by optimizing dosing regimen of piperacillin/tazobactam:prolonged vs. regular infusion].
Lü Y; Yan Z; Wang DH; Dong WL; Yang Y; Xia R
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2013 Aug; 25(8):479-83. PubMed ID: 24021044
[TBL] [Abstract][Full Text] [Related]
7. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of intravenous infusion of doripenem.
Restrepo MI
Clin Infect Dis; 2009 Aug; 49 Suppl 1():S17-27. PubMed ID: 19619018
[TBL] [Abstract][Full Text] [Related]
9. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
Kollef MH; Nováček M; Kivistik Ü; Réa-Neto Á; Shime N; Martin-Loeches I; Timsit JF; Wunderink RG; Bruno CJ; Huntington JA; Lin G; Yu B; Butterton JR; Rhee EG
Lancet Infect Dis; 2019 Dec; 19(12):1299-1311. PubMed ID: 31563344
[TBL] [Abstract][Full Text] [Related]
10. Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia.
Boselli E; Breilh D; Cannesson M; Xuereb F; Rimmelé T; Chassard D; Saux MC; Allaouchiche B
Intensive Care Med; 2004 May; 30(5):976-9. PubMed ID: 15057512
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia.
Speich R; Imhof E; Vogt M; Grossenbacher M; Zimmerli W
Eur J Clin Microbiol Infect Dis; 1998 May; 17(5):313-7. PubMed ID: 9721959
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.
Bao H; Lv Y; Wang D; Xue J; Yan Z
Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):459-466. PubMed ID: 27796647
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections.
Malangoni MA; Song J; Herrington J; Choudhri S; Pertel P
Ann Surg; 2006 Aug; 244(2):204-11. PubMed ID: 16858182
[TBL] [Abstract][Full Text] [Related]
14. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.
Jaccard C; Troillet N; Harbarth S; Zanetti G; Aymon D; Schneider R; Chiolero R; Ricou B; Romand J; Huber O; Ambrosetti P; Praz G; Lew D; Bille J; Glauser MP; Cometta A
Antimicrob Agents Chemother; 1998 Nov; 42(11):2966-72. PubMed ID: 9797234
[TBL] [Abstract][Full Text] [Related]
15. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
Kaye KS; Bhowmick T; Metallidis S; Bleasdale SC; Sagan OS; Stus V; Vazquez J; Zaitsev V; Bidair M; Chorvat E; Dragoescu PO; Fedosiuk E; Horcajada JP; Murta C; Sarychev Y; Stoev V; Morgan E; Fusaro K; Griffith D; Lomovskaya O; Alexander EL; Loutit J; Dudley MN; Giamarellos-Bourboulis EJ
JAMA; 2018 Feb; 319(8):788-799. PubMed ID: 29486041
[TBL] [Abstract][Full Text] [Related]
16. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
[TBL] [Abstract][Full Text] [Related]
17. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
Yost RJ; Cappelletty DM;
Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
[TBL] [Abstract][Full Text] [Related]
18. Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center.
Siami FS; LaFleur BJ; Siami GA
Clin Ther; 2002 Jan; 24(1):59-72. PubMed ID: 11833836
[TBL] [Abstract][Full Text] [Related]
19. Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial.
Xu ZR; Ran XW; Xian Y; Yan XD; Yuan GY; Mu SM; Shen JF; Zhang BS; Gan WJ; Wang J
J Antimicrob Chemother; 2016 Jun; 71(6):1688-96. PubMed ID: 26888908
[TBL] [Abstract][Full Text] [Related]
20. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic.
Matthews SJ; Lancaster JW
Clin Ther; 2009 Jan; 31(1):42-63. PubMed ID: 19243706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
